Abstract
Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.
Original language | English (US) |
---|---|
Pages (from-to) | 65-69 |
Number of pages | 5 |
Journal | Leukemia Research |
Volume | 28 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - May 2004 |
Keywords
- Atypical CML
- ETV6-PDGFRB fusion gene
- Imatinib mesylate
- t(5;12)
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology